Erlotinib

Results: 189



#Item
51AstraZeneca submission to the Post-Market Review of Authority Required PBS listings AstraZeneca welcomes the opportunity to contribute to the Post-Market Review of Authority Required Pharmaceutical Benefits Schedule (PBS

AstraZeneca submission to the Post-Market Review of Authority Required PBS listings AstraZeneca welcomes the opportunity to contribute to the Post-Market Review of Authority Required Pharmaceutical Benefits Schedule (PBS

Add to Reading List

Source URL: pbs.gov.au

Language: English - Date: 2015-03-02 18:33:44
52The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2013-09-19 09:55:19
53Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2014-07-31 08:37:39
54Microsoft Word - Figure 1 Orzaez CDDis

Microsoft Word - Figure 1 Orzaez CDDis

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2012-10-25 05:59:49
55OPEN  Citation: Cell Death and Disease[removed], e1260; doi:[removed]cddis[removed] & 2014 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis

OPEN Citation: Cell Death and Disease[removed], e1260; doi:[removed]cddis[removed] & 2014 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2014-05-29 08:44:58
56The HSP90 Inhibitor, AT13387, Displays Single Agent Activity in Erlotinib-Sensitive and -Resistant Models of EGFR-Activated NSCLC Keisha Hearn, Tomoko Smyth, Jon Lewis, Vanessa Martins, Neil Thompson, Mohammad Azab, John

The HSP90 Inhibitor, AT13387, Displays Single Agent Activity in Erlotinib-Sensitive and -Resistant Models of EGFR-Activated NSCLC Keisha Hearn, Tomoko Smyth, Jon Lewis, Vanessa Martins, Neil Thompson, Mohammad Azab, John

Add to Reading List

Source URL: astx.com

Language: English
57The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC[removed]Tomoko Smyth, Jon Lewis, Keisha Hearn, Aurélie Courtin, Neil Thompson, John Lyons, Nicola Wallis 1As

The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC[removed]Tomoko Smyth, Jon Lewis, Keisha Hearn, Aurélie Courtin, Neil Thompson, John Lyons, Nicola Wallis 1As

Add to Reading List

Source URL: astx.com

Language: English - Date: 2014-06-09 09:13:18
58Microsoft PowerPoint - NWallis TAT O11-5 Final

Microsoft PowerPoint - NWallis TAT O11-5 Final

Add to Reading List

Source URL: astx.com

Language: English - Date: 2014-06-09 11:38:56
59November 2012   Volume 16, Issue 9        The investment report that gives you the essenƟals to wisely invest in biotechnology securiƟes.

November 2012  Volume 16, Issue 9        The investment report that gives you the essenƟals to wisely invest in biotechnology securiƟes.

Add to Reading List

Source URL: www.biotechnav.com

Language: English - Date: 2013-01-16 17:13:33
60Lung Cancer Making Education Easy In this issue: HDREB for recurrent bronchial carcinoma

Lung Cancer Making Education Easy In this issue: HDREB for recurrent bronchial carcinoma

Add to Reading List

Source URL: www.altg.com.au

Language: English - Date: 2012-06-25 05:35:25